Last 12 months
Inside the activity.
0 purchase rows · 31 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2017 Filed Aug 21, 2017 15:21 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
GrantResMed Common Stock | 7,253 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-032789 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,365 F1 · shares: Represents performance-based restricted stock units granted on November 16, 2016. The shares were earned on August 17, 2017, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 17, 2017 Filed Aug 21, 2017 15:19 UTC |
Hollingshead JamesPresident, Americas
|
GrantResMed Common Stock | 7,213 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-032787 · doc1.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,937 F2 · shares: Represents performance-based restricted stock units granted on February 16, 2017. The shares were earned on August 17, 2017, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 17, 2017 Filed Aug 21, 2017 15:19 UTC |
Hollingshead JamesPresident, Americas
|
GrantResMed Common Stock | 14,506 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-032787 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,724 F1 · shares: Represents performance-based restricted stock units granted on November 16, 2016. The shares were earned on August 17, 2017, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 17, 2017 Filed Aug 21, 2017 15:18 UTC |
Farrell Michael J.Chief Executive Officer
|
GrantResMed Common Stock | 27,199 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-032786 · doc1.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,741 F1 · shares: Represents performance-based restricted stock units granted on November 16, 2016. The shares were earned on August 17, 2017, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. F2 · balance_after: Includes 91.28 shares of ResMed stock purchased on April 28,2017, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| August 17, 2017 Filed Aug 21, 2017 15:16 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
GrantResMed Common Stock | 36,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-032785 · doc1.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,149 F1 · shares: Represents performance-based restricted stock units initially granted on November 16, 2016. The shares were earned on August 17, 2017, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 18:33 UTC |
SULPIZIO RICHARDDirector
|
Exercise / conversionResMed Common Stock Options · Derivative | 24,390 | $0.00 Strike: $33.70 | $0.00 |
DisclosureSEC source: 0001140361-17-031347 · doc1.xml · derivative · entry 3 SULPIZIO RICHARD · CIK 0001191329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 24,390 shares Expires 2017-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents date options first became exercisable. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 18:33 UTC |
SULPIZIO RICHARDDirector
|
SaleResMed Common Stock | 24,390 | $73.85 | $1,801,201.50 |
DisclosureSEC source: 0001140361-17-031347 · doc1.xml · nonDerivative · entry 2 SULPIZIO RICHARD · CIK 0001191329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,429 F1 · price: This transaction was executed in multiple trades at prices ranging from $73.53 to $74.20. The price reported above reflects the weighted average sale price. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 18:33 UTC |
SULPIZIO RICHARDDirector
|
Exercise / conversionResMed Common Stock | 24,390 | $33.70 | $821,943.00 |
DisclosureSEC source: 0001140361-17-031347 · doc1.xml · nonDerivative · entry 1 SULPIZIO RICHARD · CIK 0001191329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,819 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2017 Filed Aug 7, 2017 21:25 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResmed Stock Option Plan · Derivative | 20,000 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-030381 · doc1.xml · derivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,460 Underlying: ResMed Common Stock · 20,000 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| August 04, 2017 Filed Aug 7, 2017 21:25 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 20,000 | $75.15 | $1,503,000.00 |
DisclosureSEC source: 0001140361-17-030381 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,557 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from 74.69 to 75.44. The price reported above represents the weighted average sales price. Read SEC document |
| August 04, 2017 Filed Aug 7, 2017 21:25 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResMed Common Stock | 20,000 | $27.58 | $551,600.00 |
DisclosureSEC source: 0001140361-17-030381 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 03, 2017 Filed Aug 4, 2017 20:08 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 6,364 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-030251 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,092 Underlying: ResMed Common Stock · 6,364 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/4 per year. Read SEC document |
| August 03, 2017 Filed Aug 4, 2017 20:08 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 6,364 | $72.10 | $458,844.40 |
DisclosureSEC source: 0001140361-17-030251 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,112 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 03, 2017 Filed Aug 4, 2017 20:08 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 6,364 | $27.58 | $175,519.12 |
DisclosureSEC source: 0001140361-17-030251 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 01, 2017 Filed Aug 2, 2017 01:16 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 1,250 | $77.49 | $96,862.50 |
DisclosureSEC source: 0001140361-17-029733 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,258 F1 · kind: The transaction was conducted under a Rule10b5-1 Plan. Read SEC document |
| July 14, 2017 Filed Jul 17, 2017 17:59 UTC |
Hollingshead JamesPresident, Americas
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,265 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001140361-17-027950 · doc1.xml · derivative · entry 4 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,019 Underlying: ResMed Common Stock · 5,265 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest ? per year. Read SEC document |
| July 14, 2017 Filed Jul 17, 2017 17:59 UTC |
Hollingshead JamesPresident, Americas
|
SaleResMed Common Stock | 1,875 | $77.43 | $145,181.25 |
DisclosureSEC source: 0001140361-17-027950 · doc1.xml · nonDerivative · entry 3 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,218 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| July 14, 2017 Filed Jul 17, 2017 17:59 UTC |
Hollingshead JamesPresident, Americas
|
SaleResMed Common Stock | 5,265 | $77.43 | $407,668.95 |
DisclosureSEC source: 0001140361-17-027950 · doc1.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,093 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| July 14, 2017 Filed Jul 17, 2017 17:59 UTC |
Hollingshead JamesPresident, Americas
|
Exercise / conversionResMed Common Stock | 5,265 | $43.63 | $229,711.95 |
DisclosureSEC source: 0001140361-17-027950 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. F2 · balance_after: Includes 298 shares of ResMed stock purchased on April 28, 2017, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| July 05, 2017 Filed Jul 6, 2017 22:13 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResmed Stock Option Plan · Derivative | 20,000 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-027380 · doc1.xml · derivative · entry 4 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,460 Underlying: ResMed Common Stock · 20,000 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F4 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| July 05, 2017 Filed Jul 6, 2017 22:13 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 400 | $77.15 | $30,860.00 |
DisclosureSEC source: 0001140361-17-027380 · doc1.xml · nonDerivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,557 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · price: This transaction was executed in multiple trades at prices ranging from 76.83 to 77.26. The price reported above represents the weighted average sales price. Read SEC document |
| July 05, 2017 Filed Jul 6, 2017 22:13 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 19,600 | $76.49 | $1,499,204.00 |
DisclosureSEC source: 0001140361-17-027380 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,957 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from 75.83 to 76.76. The price reported above represents the weighted average sales price. Read SEC document |
| July 05, 2017 Filed Jul 6, 2017 22:13 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResMed Common Stock | 20,000 | $27.58 | $551,600.00 |
DisclosureSEC source: 0001140361-17-027380 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 03, 2017 Filed Jul 5, 2017 22:56 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 1,250 | $77.44 | $96,800.00 |
DisclosureSEC source: 0001140361-17-027222 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,508 F1 · kind: The transaction was conducted under a Rule10b5-1 Plan. Read SEC document |
| July 03, 2017 Filed Jul 5, 2017 19:04 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 6,364 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-027106 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,456 Underlying: ResMed Common Stock · 6,364 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/4 per year. Read SEC document |
| July 03, 2017 Filed Jul 5, 2017 19:04 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 6,364 | $77.36 | $492,319.04 |
DisclosureSEC source: 0001140361-17-027106 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,112 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $77.06 to $77.67. The price reported above reflects the weighted average sale price. Read SEC document |
| July 03, 2017 Filed Jul 5, 2017 19:04 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 6,364 | $27.58 | $175,519.12 |
DisclosureSEC source: 0001140361-17-027106 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 22, 2017 Filed Jun 27, 2017 23:34 UTC |
SULPIZIO RICHARDDirector
|
SaleResMed Common Stock | 65,887 | $77.82 | $5,127,260.45 |
DisclosureSEC source: 0001140361-17-026325 · doc1.xml · nonDerivative · entry 2 SULPIZIO RICHARD · CIK 0001191329 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Magali Charitable Remainder Unitrust Disclosed balance after: 0 F1 · kind: Sale executed by Bank of America, N.A., Trustee of the Magali Charitable Remainder Unitrust. Mr. Sulpizio has no control over the timing of any disposition of the shares gifted. F1 · shares: Sale executed by Bank of America, N.A., Trustee of the Magali Charitable Remainder Unitrust. Mr. Sulpizio has no control over the timing of any disposition of the shares gifted. F2 · ownership.nature: Bank of America, N.A. is Trustee of the Magali Charitable Remainder Unitrust and Mr. Sulpizio has no control over the disposition of the equities held. Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 23:29 UTC |
SULPIZIO RICHARDDirector
|
GiftResMed Common Stock | 65,887 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-026035 · doc1.xml · nonDerivative · entry 1 SULPIZIO RICHARD · CIK 0001191329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,429 F1 · kind: Represents a gift to the Magali Charitable Remainder Unitrust, Bank of America, N.A., Trustee. Mr. Sulpizio has no control over the timing of any disposition of the shares transferred. Read SEC document |
| June 21, 2017 Filed Jun 27, 2017 01:59 UTC Amendment |
SULPIZIO RICHARDDirector
|
GiftResMed Common Stock | 65,887 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-026144 · doc1.xml · nonDerivative · entry 2 SULPIZIO RICHARD · CIK 0001191329 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Magali Charitable Remainder Unitrust Disclosed balance after: 65,887 F1 · kind: Represents a gift to the Magali Charitable Remainder Unitrust, Bank of America, N.A., Trustee. Mr. Sulpizio has no control over the timing of any disposition of the shares transferred. F1 · shares: Represents a gift to the Magali Charitable Remainder Unitrust, Bank of America, N.A., Trustee. Mr. Sulpizio has no control over the timing of any disposition of the shares transferred. F2 · ownership.nature: Securities held by Bank of America, N.A., Trustee of the Magali Charitable Remainder Unitrust. Mr. Sulpizio has no control over the timing of any disposition of the shares transferred. Read SEC document |
| June 21, 2017 Filed Jun 27, 2017 01:59 UTC Amendment |
SULPIZIO RICHARDDirector
|
GiftResMed Common Stock | 65,887 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-026144 · doc1.xml · nonDerivative · entry 1 SULPIZIO RICHARD · CIK 0001191329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,429 F1 · kind: Represents a gift to the Magali Charitable Remainder Unitrust, Bank of America, N.A., Trustee. Mr. Sulpizio has no control over the timing of any disposition of the shares transferred. F1 · shares: Represents a gift to the Magali Charitable Remainder Unitrust, Bank of America, N.A., Trustee. Mr. Sulpizio has no control over the timing of any disposition of the shares transferred. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 15:20 UTC |
PACE GARY WDirector
|
Exercise / conversionResMed Common Stock Options · Derivative | 22,660 | $0.00 Strike: $33.70 | $0.00 |
DisclosureSEC source: 0001140361-17-025248 · doc1.xml · derivative · entry 6 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 22,660 shares Expires 2017-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest one full year following the grant date. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 15:20 UTC |
PACE GARY WDirector
|
SaleResMed Common Stock | 22,660 | $76.00 | $1,722,160.00 |
DisclosureSEC source: 0001140361-17-025248 · doc1.xml · nonDerivative · entry 4 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,587 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 15:20 UTC |
PACE GARY WDirector
|
Exercise / conversionResMed Common Stock | 22,660 | $33.70 | $763,642.00 |
DisclosureSEC source: 0001140361-17-025248 · doc1.xml · nonDerivative · entry 3 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,247 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 15:20 UTC |
PACE GARY WDirector
|
Exercise / conversionResMed Common Stock Options · Derivative | 1,730 | $0.00 Strike: $33.70 | $0.00 |
DisclosureSEC source: 0001140361-17-025248 · doc1.xml · derivative · entry 5 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,660 Underlying: ResMed Common Stock · 1,730 shares Expires 2017-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest one full year following the grant date. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 15:20 UTC |
PACE GARY WDirector
|
SaleResMed Common Stock | 1,730 | $76.00 | $131,480.00 |
DisclosureSEC source: 0001140361-17-025248 · doc1.xml · nonDerivative · entry 2 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,587 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 15:20 UTC |
PACE GARY WDirector
|
Exercise / conversionResMed Common Stock | 1,730 | $33.70 | $58,301.00 |
DisclosureSEC source: 0001140361-17-025248 · doc1.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,317 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 05, 2017 Filed Jun 6, 2017 18:11 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 6,365 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-023919 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,820 Underlying: ResMed Common Stock · 6,365 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/4 per year. Read SEC document |
| June 05, 2017 Filed Jun 6, 2017 18:11 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 6,365 | $72.62 | $462,226.30 |
DisclosureSEC source: 0001140361-17-023919 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,112 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $72.47 to $72.82. The price reported above reflects the weighted average sale price. Read SEC document |
| June 05, 2017 Filed Jun 6, 2017 18:11 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 6,365 | $27.58 | $175,546.70 |
DisclosureSEC source: 0001140361-17-023919 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 05, 2017 Filed Jun 6, 2017 18:44 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResmed Stock Option Plan · Derivative | 20,000 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-023921 · doc1.xml · derivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,460 Underlying: ResMed Common Stock · 20,000 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| June 05, 2017 Filed Jun 6, 2017 18:44 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 20,000 | $72.65 | $1,452,960.00 |
DisclosureSEC source: 0001140361-17-023921 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,557 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from 72.43 to 72.79. The price reported above represents the weighted average sales price. Read SEC document |
| June 05, 2017 Filed Jun 6, 2017 18:44 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResMed Common Stock | 20,000 | $27.58 | $551,600.00 |
DisclosureSEC source: 0001140361-17-023921 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 15:43 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
GrantResMed Common Stock Options · Derivative | 6,982 | $0.00 Strike: $71.89 | $0.00 |
DisclosureSEC source: 0001140361-17-023437 · doc1.xml · derivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,982 Underlying: ResMed Common Stock · 6,982 shares Expires 2024-06-01 F2 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each June 1, 2018, 2019 and 2020. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 17:12 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 1,250 | $71.02 | $88,775.00 |
DisclosureSEC source: 0001140361-17-023731 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,758 F1 · kind: The transaction was conducted under a Rule10b5-1 Plan. F2 · balance_after: Includes 225 shares of ResMed stock purchased on April 28, 2017, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| May 04, 2017 Filed May 5, 2017 16:38 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResmed Stock Option Plan · Derivative | 20,000 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-018559 · doc1.xml · derivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,460 Underlying: ResMed Common Stock · 20,000 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| May 04, 2017 Filed May 5, 2017 16:38 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 20,000 | $68.75 | $1,374,920.00 |
DisclosureSEC source: 0001140361-17-018559 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,557 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from 68.44 to 69.00. The price reported above represents the weighted average sales price. Read SEC document |
| May 04, 2017 Filed May 5, 2017 16:38 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResMed Common Stock | 20,000 | $27.58 | $551,600.00 |
DisclosureSEC source: 0001140361-17-018559 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| May 03, 2017 Filed May 5, 2017 15:58 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 6,365 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-018553 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,185 Underlying: ResMed Common Stock · 6,365 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/4 per year. Read SEC document |
| May 03, 2017 Filed May 5, 2017 15:58 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 6,365 | $69.55 | $442,679.39 |
DisclosureSEC source: 0001140361-17-018553 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,896 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $69.45 to $69.63. The price reported above reflects the weighted average sale price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.